Type 2 diabetes mellitus;Diabetes mellitus tipo 2

Revista Brasileira de Medicina

Volumn 58, Issue SPEC. ISS., 2001, Pages 23-32

  Da Silva, Maria Elizabeth Rossi ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Diagnosis; Treatment; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; AGLUCIL; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; APEX; BIOHULIN; CHLORPROPAMIDE; DIMEFOR; GLIBENCLAMIDE; GLICLAZIDE; GLIFAGE; GLIMEPIL; GLIMEPIRIDE; GLIPIZIDE; HUMAN INSULIN; INSULIN; INSUMAN COMB; METFORMIN; METFORMINA; NATEGLINIDE; PIOGLITAZONE; RECOMBINANT HUMAN INSULIN; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE;

DIABETES CONTROL; DIET THERAPY; HUMAN; KINESIOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

EID: 7944238846     PISSN: 00347264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Gross, JL; Ferreira, SRG; Franco, LJ; Schmidt, MI; Motta, DG; Quintão, E; Netto, AP. Diagnóstico e classificação do Diabetes Mellitus e tratamento do Diabetes Mellitus Tipo 2. Recomendações da Sociedade Brasileira de Diabetes. Arq. Bras. Endocr. Metabol 2000; 44 (sup; 1): S8-S27.
2. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2001; 24: S5-S20.
3. Beck-Nielsen H, Henriksen AV, Hother-Nielsen O - Pathophysiology of non-insulin-dependent diabetes mellitus (NIDDM). Diabetes Res. Clin. Prac. 1995; 28 (Suppl): S13-25.
4. Haffner SM. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr. Rev. 1998; 19:583-92.
5. Diabetes Control and Complications Trial Research Group - The effect of intensive treatment of diabetes on the development and progression of long term complications of insulin-dependent diabetes mellitus. N. Eng.l J. Med. 1993; 329: 977-86.
6. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet 1998; 358: 837-53.
7. Fuller JH, Shipley MJ, Rose G, Jarret RJ, Keen H - Coronary-heart-disease rish and impaired glucose tolerance The Whitehall Study. Lancet 1980; 1:1373-6.
8. Harris MI - Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993; 16: 642-52.
9. Decode Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354:617-21.
10. Prato, SD. Metabolic control in type 2 diabetes: the impact of prandial glucose. Current Opinion in Endocrinology & Diabetes 1999; 6 (Suppl 1): S1-S6.
11. Ursich MJM, Silva MER, Rocha DM - Tratamento do diabetes mellitus. In: Wajchenberg BL, Livraria Roca Ltda. Tratado de Endocrinologia Clínica 1992; São Paulo, pp 789-824.
12. American Diabetes Association - Nutrition recommendations and principles for people with diabetes mellitus (Position Statement). Diabetes Care 2001; 24 (Suppl 1): S44-47.
13. American Diabetes Association - Diabetes mellitus and exercise (Position Statement). Diabetes Care 2001; 24 (Suppl 1): S51-55.
14. Horton ES - Exercise and diabetes mellitus. Med. Clin. N. Am. 1988; 72: 1301-21.
15. Lebovitz, HE. Insulin secretagogues: old and new. Diabetes Reviews 1999; 7:139-53.
16. Araújo, LMB; Britto MMS; Cruz, TRR Tratamento do Diabetes Mellitus do Tipo 2: Novas Opções. Arq. Bras. Endocr. Metabol 2000; 44: 509-18.
17. DeFronzo, RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. 1999; 131: 281-303.
18. Josse RG - Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial. Diabetes Res. Clin. Prac. 1995; 28 (Suppl): S167-72.
19. Meneilly, GS; Ryan, EA; Raddziuk, J.; Lau, DCW; Yale, JF; Morais, J; Chiasson, JL; Rabasa-Lhoret, R; Maheux, P; Tessier, D; Wolever, T; Josse, RG; Elahi, D. Effect of Acarbose on Insulin Sensitivity in Elderly Patients with Diabetes. Diabetes Care 2000; 23:1162-7.
20. Moses RG, Gomis R, Frandsen KB, Schlienger JL, Dedov I. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes, Diabetes Care 2001; 24:11-5.
21. Kalbag, JB, Walter YH, Nedelman JR, McLeod JF. Mealtime glucose regulation with nateglinide in healthy volunteers. Diabetes Care 2001; 24:73-7.
22. Petersen, KF; Krssak, M; Inzucchi, S; Cline, GW; Dufour, S; Shulman, GI. Mechanism of Troglitazone Action in Type 2 Diabetes. Diabetes 2000; 49: 827-31.
23. Bradley, GN. Thiazolidinediones for type 2 diabetes: No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4. BMJ 322:236, 2001.
24. Riddle, M. Combining Sulfonylureas and Other Oral Agents. The American Journal of Medicine 2000; 108:15S-22S.
25. Fonseca, V; Rosenstock, J; Patwardhan, R; Salzman, A. Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus. Jama; 2000; 283:1695-702.
26. American Diabetes Association - Diabetic nephropathy. Diabetes Care 24 (Suppl 1): S69-72; 2001.
27. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 2000; 342:145-53.
28. Parving, HH; Rossing, P. Therapeutic Benefits of ACE Inhibitors and Other Anthypertensive Drugs in Patients With Type 2 Diabetes. Diabetes Care 2001; 24: 177-8.
29. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and macrovascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-12.
30. American Diabetes Association - Management of Dislipidemia in adults with diabetes (Consensus Statement). Diabetes Care 2001; 24 (Suppl 1): S58-61.
31. American Diabetes Association - Aspirin therapy in diabetes. Diabetes Care 2001; 24 (Suppl 1): S62-3.